NewEdge Advisors LLC Sells 6,643 Shares of Halozyme Therapeutics, Inc. $HALO

NewEdge Advisors LLC lowered its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 57.4% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,933 shares of the biopharmaceutical company’s stock after selling 6,643 shares during the quarter. NewEdge Advisors LLC’s holdings in Halozyme Therapeutics were worth $319,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC raised its stake in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 124 shares during the last quarter. Abel Hall LLC boosted its stake in shares of Halozyme Therapeutics by 4.2% in the 4th quarter. Abel Hall LLC now owns 3,216 shares of the biopharmaceutical company’s stock worth $216,000 after buying an additional 129 shares during the last quarter. StoneX Group Inc. grew its holdings in shares of Halozyme Therapeutics by 3.8% in the fourth quarter. StoneX Group Inc. now owns 3,650 shares of the biopharmaceutical company’s stock worth $246,000 after acquiring an additional 132 shares during the period. Twin Capital Management Inc. grew its holdings in shares of Halozyme Therapeutics by 1.4% in the first quarter. Twin Capital Management Inc. now owns 11,422 shares of the biopharmaceutical company’s stock worth $738,000 after acquiring an additional 161 shares during the period. Finally, Coldstream Capital Management Inc. grew its holdings in shares of Halozyme Therapeutics by 1.9% in the third quarter. Coldstream Capital Management Inc. now owns 8,914 shares of the biopharmaceutical company’s stock worth $654,000 after acquiring an additional 165 shares during the period. Institutional investors own 97.79% of the company’s stock.

Insider Buying and Selling at Halozyme Therapeutics

In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $104.18, for a total value of $2,083,600.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $79,987,320.40. The trade was a 2.54% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the sale, the director owned 40,418 shares in the company, valued at $4,154,970.40. This represents a 3.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 64,103 shares of company stock valued at $5,226,496 in the last 90 days. Insiders own 2.50% of the company’s stock.

Halozyme Therapeutics Price Performance

HALO stock opened at $108.17 on Monday. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $108.49. The company’s fifty day moving average price is $83.19 and its 200-day moving average price is $73.74. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. The company has a market capitalization of $12.28 billion, a PE ratio of 32.29, a price-to-earnings-growth ratio of 0.43 and a beta of 0.85.

Halozyme Therapeutics (NASDAQ:HALO) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. Halozyme Therapeutics had a net margin of 24.86% and a return on equity of 260.98%. Halozyme Therapeutics’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.54 earnings per share. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 7.77 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on HALO shares. Citigroup reissued a “market outperform” rating on shares of Halozyme Therapeutics in a report on Friday, August 7th. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price target for the company from $83.00 to $110.00 in a research report on Friday, August 7th. HC Wainwright boosted their target price on shares of Halozyme Therapeutics from $95.00 to $115.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Finally, Weiss Ratings cut shares of Halozyme Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, August 14th. Nine analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $91.20.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.